{"schema_version":"secwatch.filing_event.v1","accession":"0000064803-23-000046","form_type":"8-K","ticker":"CVS","cik":"0000064803","company_name":"CVS HEALTH Corp","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.745613+00:00","generated_at":"2026-06-09T03:30:51.580210+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVS Health Q3 revenue $89.8B (+10.6%), GAAP EPS $1.75, Adj EPS $2.21, FY GAAP EPS guidance revised to $6.37-$6.61","bullets":["Total revenues $89.8B, up 10.6% YoY; GAAP diluted EPS $1.75 vs loss of $2.59 prior year.","Adjusted EPS $2.21 vs $2.17 prior year; YTD cash flow from operations $16.1B.","FY GAAP EPS guidance revised to $6.37-$6.61 from $6.53-$6.75; adjusted EPS guidance confirmed at $8.50-$8.70.","Launched Cordavis to commercialize biosimilars; Aetna's 2024 Medicare offerings expanded.","Appointed Scott Kirby (United Airlines CEO) and Michael Mahoney (Boston Scientific CEO) to board."],"urls":{"canonical":"https://secwatch.observer/filing/0000064803-23-000046","json":"https://secwatch.observer/filing/0000064803-23-000046.json","markdown":"https://secwatch.observer/filing/0000064803-23-000046.md","text":"https://secwatch.observer/filing/0000064803-23-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000046/0000064803-23-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000046/cvs-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:30:51.580210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98ebfb709123ff6c31d3fedc12bf172510af0a99","claim":"CVS HEALTH Corp reported three months ended September 30, 2023 results: revenue $89.8 billion, EPS GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21. Guidance reaffirmed.","evidence_excerpt":"(NYSE: CVS) today announced operating results for the three months ended September 30, 2023. Third quarter highlights Key financial data • Total revenues increased to $89.8 billion, up 10.6% compared to prior year • GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21 Year-to-date highlights • Total revenues increased to $264.0 billion, up 10.6% compared to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000046/0000064803-23-000046-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Revenue","value":"$89.8 billion"},{"label":"EPS","value":"GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}